☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
conditional approval
BMS' Abecma (Idecabtagene Vicleucel) Receives EC's Conditional Approval for Relapsed and Refractory Multiple Myeloma
August 20, 2021
BeiGene's Kyprolis (carfilzomib) Receives NMPA's Conditional Approval for the Treatment of Relapsed or Refractory Multiple Myeloma
July 9, 2021
AveXis Receives EC's Conditional Approval and Activates “Day One” Access Program for Zolgensma (onasemnogene abeparvovec) to Treat...
May 20, 2020
Merck's Ervebo [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Receives EC's Conditional Approval to Prevent Ebola Virus Disease
November 12, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.